VIENNA & DUESSELDORF, Germany--(BUSINESS WIRE)--Press Kit Materials are Available at: http://www.tradeshownews.com/events/BIO-Europe-2011/Activartis/
| Company: | Activartis Biotech GmbH | |
| Event: |
BIO-Europe 2011 Oct 31 - Nov 2, 2011 Duesseldorf, DE |
|
| Web: |
About Activartis Biotech GmbH
Activartis GmbH – former Trimed Biotech GmbH – is developing a cancer immunotherapy concept which is currently in phase II clinical trials. Initially directed against aggressive brain cancer, it will in principle be applicable to all types of cancerous diseases. It therefore has blockbuster potential. The therapeutic platform combines a completely novel proprietary and IP-protected approach – the utilisation of a bacterial danger signal in combination with the patient’s tumour antigens – with a proven successful concept (dendritic cells) to mobilise the patients’ immune system to combat the disease.